52 Participants Needed

ERAS-801 for Glioblastoma

Recruiting at 7 trial locations
EC
Overseen ByErasca Clinical Team
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing ERAS-801, a new drug for treating brain cancer. It focuses on patients whose brain cancer has returned after treatment. The drug works by blocking signals that help cancer cells grow. Researchers want to find the safest and most effective dose of ERAS-801. ERAs may be useful for treating cancer patients.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Who Is on the Research Team?

LB

Les Brail

Principal Investigator

Medical Director

Are You a Good Fit for This Trial?

This trial is for adults over 18 with recurrent glioblastoma who can take pills orally and have good organ function. They must be able to consent to the study and follow its procedures. People with allergies to ERAS-801, past EGFR inhibitor treatments for glioblastoma, significant heart disease, active infections needing treatment, or gastrointestinal issues affecting drug absorption cannot join.

Inclusion Criteria

My organs are working well.
Willing and able to give written informed consent
I can take pills by mouth.
See 2 more

Exclusion Criteria

I have been treated with an EGFR inhibitor for my brain cancer.
I have stomach or intestine problems that could affect how I absorb pills.
I am currently being treated for an infection.
See 5 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

ERAS-801 is administered in sequential ascending doses to determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD)

4 weeks
Weekly visits for dose escalation monitoring

Dose Expansion

ERAS-801 is administered at the recommended dose to participants with EGFR alterations

24 months
Regular visits for monitoring and assessment

Follow-up

Participants are monitored for safety and effectiveness after treatment

24 months

What Are the Treatments Tested in This Trial?

Interventions

  • ERAS-801
Trial Overview The trial tests different doses of a new medication called ERAS-801 in patients with recurrent glioblastoma to find the safest and most effective dose level. It also looks at how well it works against tumors and studies how the body processes the drug.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: Dose Expansion (Part 2)Experimental Treatment1 Intervention
Group II: Dose Escalation (Part 1)Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Erasca, Inc.

Lead Sponsor

Trials
8
Recruited
1,200+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security